PL3288553T3 - Połączenia kannabinoidów i n-acyloetanoloamin - Google Patents

Połączenia kannabinoidów i n-acyloetanoloamin

Info

Publication number
PL3288553T3
PL3288553T3 PL16786064.2T PL16786064T PL3288553T3 PL 3288553 T3 PL3288553 T3 PL 3288553T3 PL 16786064 T PL16786064 T PL 16786064T PL 3288553 T3 PL3288553 T3 PL 3288553T3
Authority
PL
Poland
Prior art keywords
acylethanolamines
cannabinoids
combinations
Prior art date
Application number
PL16786064.2T
Other languages
English (en)
Polish (pl)
Inventor
Ascher Shmulewitz
Elran HABER
Ephraim Brener
Original Assignee
Scisparc Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scisparc Ltd filed Critical Scisparc Ltd
Publication of PL3288553T3 publication Critical patent/PL3288553T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/348Cannabaceae
    • A61K36/3482Cannabis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
PL16786064.2T 2015-04-29 2016-04-19 Połączenia kannabinoidów i n-acyloetanoloamin PL3288553T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154144P 2015-04-29 2015-04-29
PCT/IL2016/050414 WO2016174661A1 (en) 2015-04-29 2016-04-19 Combinations of cannabinoids and n-acylethanolamines

Publications (1)

Publication Number Publication Date
PL3288553T3 true PL3288553T3 (pl) 2023-03-20

Family

ID=57199061

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16786064.2T PL3288553T3 (pl) 2015-04-29 2016-04-19 Połączenia kannabinoidów i n-acyloetanoloamin

Country Status (12)

Country Link
US (7) US11234956B2 (enExample)
EP (2) EP3288553B1 (enExample)
JP (2) JP6938465B2 (enExample)
CN (2) CN116549437A (enExample)
AU (3) AU2016254685B2 (enExample)
CA (1) CA2984088C (enExample)
DK (1) DK3288553T3 (enExample)
ES (1) ES2935605T3 (enExample)
IL (2) IL291864A (enExample)
MA (1) MA41997A (enExample)
PL (1) PL3288553T3 (enExample)
WO (1) WO2016174661A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3288553T3 (pl) * 2015-04-29 2023-03-20 Scisparc Ltd Połączenia kannabinoidów i n-acyloetanoloamin
WO2019136351A1 (en) * 2018-01-05 2019-07-11 Altus Labs, Llc Personal care compositions
CA3126772A1 (en) * 2018-01-29 2019-08-01 Evero Compositions and methods for treating obstructive sleep apnea
MX2020010424A (es) * 2018-04-03 2021-01-15 Pure Green Pharmaceuticals Inc Comprimido o composicion que contiene n-acil etanolamina y cannabinoides.
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
WO2020214569A1 (en) 2019-04-15 2020-10-22 Metagenics, Inc. Novel hemp and pea formulation and its use
US20220211647A1 (en) * 2019-04-23 2022-07-07 SciSparc Ltd. Compositions and methods for potentiating derivatives of 4-aminophenols
WO2020227440A1 (en) * 2019-05-07 2020-11-12 Ojai Energetics Pbc Methods for optimized cannabinoid dosage determination
WO2020237247A1 (en) 2019-05-23 2020-11-26 India Globalization Capital, Inc. Compositions and methods using cannabinoids for treating stammering/stutering and symptoms of tourette syndrome
EP4017486A4 (en) * 2019-08-19 2023-09-20 Buzzelet Development And Technologies Ltd COMPOSITIONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND THEIR USES
EP3838346A1 (en) * 2019-12-20 2021-06-23 Chemo Research SL Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
CN115297854A (zh) 2020-01-10 2022-11-04 帕西拉制药股份有限公司 通过蛛网膜下腔给予缓释脂质体麻醉组合物治疗疼痛
WO2021141959A1 (en) 2020-01-10 2021-07-15 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
US11273122B2 (en) 2020-02-11 2022-03-15 Therese Mainella Combination of cannabis, derivatives thereof and additives in oral care compositions
EP4274573A4 (en) 2021-01-11 2024-12-11 Pacira Pharmaceuticals, Inc. TREATMENT OF HIP PAIN WITH LIPOSOMAL SUSTAINED-RELEASE ANESTHESIA COMPOSITIONS
US20230000936A1 (en) * 2021-06-30 2023-01-05 Demetrix, Inc. Alleviation of itching sensations using cannabinoid compounds
WO2023039419A2 (en) 2021-09-08 2023-03-16 Plantible Foods Inc. Systems and methods for measuring mat density of aquatic biomass
WO2023200906A1 (en) 2022-04-12 2023-10-19 Shackelford Pharma Inc. Treatment of seizure disorders
US12226610B2 (en) 2022-11-03 2025-02-18 Pacira Pharmaceuticals, Inc. Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
WO2024124354A1 (en) * 2022-12-16 2024-06-20 Aima Inc. Compositions and methods for treating or preventing pain or other disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776414B2 (en) * 1998-05-29 2004-09-09 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
US20090054526A1 (en) * 2005-07-14 2009-02-26 Hansen Harald S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
PL2475352T5 (pl) * 2009-09-07 2019-02-28 Epitech Group S.P.A. Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
PL3288553T3 (pl) * 2015-04-29 2023-03-20 Scisparc Ltd Połączenia kannabinoidów i n-acyloetanoloamin

Also Published As

Publication number Publication date
US20200038367A1 (en) 2020-02-06
CN107530317A (zh) 2018-01-02
CN116549437A (zh) 2023-08-08
EP3288553A4 (en) 2018-12-26
WO2016174661A1 (en) 2016-11-03
CA2984088A1 (en) 2016-11-03
IL291864A (en) 2022-06-01
US11197845B2 (en) 2021-12-14
US20180078523A1 (en) 2018-03-22
AU2023251426A1 (en) 2023-11-09
AU2023251426B2 (en) 2025-11-27
MA41997A (fr) 2021-03-31
EP4193993A3 (en) 2023-07-19
US20200030281A1 (en) 2020-01-30
ES2935605T3 (es) 2023-03-08
US20220071948A1 (en) 2022-03-10
JP2021107401A (ja) 2021-07-29
AU2021206784B2 (en) 2023-07-20
US11234956B2 (en) 2022-02-01
JP6938465B2 (ja) 2021-09-22
JP2018514589A (ja) 2018-06-07
IL255238B (en) 2022-05-01
AU2021206784A1 (en) 2021-08-12
EP4193993A2 (en) 2023-06-14
US11207290B2 (en) 2021-12-28
EP3288553B1 (en) 2022-12-28
DK3288553T3 (da) 2023-01-23
EP3288553A1 (en) 2018-03-07
CA2984088C (en) 2024-04-09
US20210393577A1 (en) 2021-12-23
AU2016254685B2 (en) 2021-04-22
AU2016254685A1 (en) 2017-11-09
US20220071949A1 (en) 2022-03-10
IL255238A0 (en) 2017-12-31
US20200022946A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL285433A (en) Converted tricycles and method of use
IL255238A0 (en) Combinations of cannabinoids and acyl-ethanol-amines
IL282572B (en) Tetrahydropyranylamino-pyrrolopyrimidinone and methods of using it
ZA201801511B (en) Flavonoid compositions and methods of use
ZA201703075B (en) Substituted chromanes and method of use
IL250415B (en) Antibodies against pd-l and methods of using them
SG11201803213XA (en) Glycan-interacting compounds and methods of use
IL282482A (en) Variants of protoxin-II and methods of use
GB201514760D0 (en) Compounds and method of use
IL282508A (en) Variants of protoxin-II and methods of use
IL305528B2 (en) Combinations of opioids and acylethanolamines
IL254783B (en) Combinations for deworming methods for using them
PT3397364T (pt) Elementos estruturados e métodos de utilização
ZA201606450B (en) Compounds and their methods of use
IL248554A0 (en) dr3 variants and their use
AU2025287414A1 (en) Combinations of cannabinoids and N-acylethanolamines
SG10201912615PA (en) Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
GB201416797D0 (en) Contianer and method of use thereof
GB201419990D0 (en) Hprseshoe and method of manufacture